[
    [
        {
            "time": "2023-10-18",
            "original_text": "药明康德A股定增发行6269.03万股 UBS AG获配1446.27万股",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股",
                    "定增",
                    "UBS AG",
                    "获配"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德A股定增发行6269.03万股 UBS AG获配1446.27万股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "公告精选丨天山生物称证监会调查仍在进行中；药明康德披露A股定增报告书",
            "features": {
                "keywords": [
                    "天山生物",
                    "证监会",
                    "调查",
                    "药明康德",
                    "A股",
                    "定增"
                ],
                "sentiment_score": -0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "农业"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "公告精选丨天山生物称证监会调查仍在进行中；药明康德披露A股定增报告书",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "太火爆了！药明康德定增底价87.81元实际发行价104.13元/股，UBS AG出资15.06亿参与认购",
            "features": {
                "keywords": [
                    "药明康德",
                    "定增",
                    "底价",
                    "发行价",
                    "UBS AG",
                    "认购"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "太火爆了！药明康德定增底价87.81元实际发行价104.13元/股，UBS AG出资15.06亿参与认购",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 10,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "药明康德(02359)签订《募集资金专户存储三方监管协议》",
            "features": {
                "keywords": [
                    "药明康德",
                    "募集资金",
                    "三方监管协议"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(02359)签订《募集资金专户存储三方监管协议》",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "外围大跌A股调整加速，两大聪明资金押注传统行业",
            "features": {
                "keywords": [
                    "外围市场",
                    "A股",
                    "调整",
                    "聪明资金",
                    "传统行业"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "综合"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "外围大跌A股调整加速，两大聪明资金押注传统行业",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "药明康德(02359)完成发行6269.03万股A股 净募资64.61亿元",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股",
                    "发行",
                    "募资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(02359)完成发行6269.03万股A股 净募资64.61亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "药明康德披露A股定增报告书：发行价格104.13元",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股",
                    "定增",
                    "发行价格"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德披露A股定增报告书：发行价格104.13元",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "药明康德披露A股定增报告书：发行价为104.13元/股",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股",
                    "定增",
                    "发行价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德披露A股定增报告书：发行价为104.13元/股",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "药明康德披露A股定增报告书：UBS AG获配15.06亿元的股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股",
                    "定增",
                    "UBS AG",
                    "获配"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德披露A股定增报告书：UBS AG获配15.06亿元的股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "药明康德(603259.SH)披露A股定增报告书：UBS AG获配15.06亿元的股份",
            "features": {
                "keywords": [
                    "药明康德",
                    "A股",
                    "定增",
                    "UBS AG",
                    "获配"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明康德(603259.SH)披露A股定增报告书：UBS AG获配15.06亿元的股份",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "金斯瑞创始人被“监视居住” 因偷运人类遗传资源惹的祸？",
            "features": {
                "keywords": [
                    "金斯瑞",
                    "创始人",
                    "监视居住",
                    "人类遗传资源"
                ],
                "sentiment_score": -0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "金斯瑞创始人被“监视居住” 因偷运人类遗传资源惹的祸？",
                "Correlation": 2,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]